  Abbreviations, acronyms & symbols                                                                                                    
  ----------------------------------- --------------------------------------------- --------- ---------------------------------------- ----------------
  ACE-i/ARB                           = Angiotensin-converting enzyme inhibitor/              HT                                       = Hypertension
                                      angiotensin receptor blockers                 IL        = Interleukin                            
  AF                                  = Atrial fibrillation                         MPV       = Mean platelet volume                   
  CABG                                = Coronary artery bypass graft                25-(OH)   = 25-hydroxy (OH)                        
  COPD                                = Chronic obstructive pulmonary disease       POAF      = Postoperative atrial fibrillation      
  DM                                  = Diabetes mellitus                           RAAS      = Renin-angiotensin-aldosterone system   
  ECG                                 = Electrocardiogram                           RDW       = Red blood cell distribution width      
  EF                                  = Ejection fraction                           SD        = Standard deviation                     
  HF                                  = Heart failure                               TIA       = Transient ischemic attack              
  HL                                  = Hyperlipidemia                              vitD      = Vitamin D                              

INTRODUCTION
============

Atrial fibrillation (AF) is the most common arrhythmia occurring after coronary artery bypass graft (CABG) surgery and it is seen in approximately 15%-60% of these patients. Postoperative AF (POAF) is associated with increased morbidity, mortality, and longer hospital stay; it is also associated with a two-to-three-fold increase in postoperative stroke. Ageing, obesity, hypertension (HT), prior AF, and heart failure (HF) are found strongly associated with higher risk of POAF^\[[@r1]\]^.

Vitamin D (vitD) has various cardiovascular pleiotropic effects by activating its nuclear receptor in cardiomyocytes and vascular endothelial cells and by regulating the renin-angiotensin-aldosterone system (RAAS), adiposity, and energy expenditure. There is inconsistent data about the association between vitD and POAF. POAF incidence was significantly higher in patients with vitD deficiency or insufficiency than in patients with normal vitD level in previous studies^\[[@r2]-[@r6]\]^. In our previous study, although there was a significant negative correlation between vitD and left atrial diameter, the vitD level was not an independent predictor of POAF^\[[@r7]\]^.

To the best of our knowledge, the relationship between preoperative vitD supplementation in patients with vitD deficiency/insufficiency and POAF has not been studied before. Therefore, we assessed the preventive effect of vitD supplementation on POAF in patients who underwent CABG surgery with vitD deficiency/insufficiency.

METHODS
=======

Our study was a randomised, blinded clinical trial. The study group consisted of 328 consecutive patients who underwent on-pump CABG surgery. Prevalence of vitD insufficiency and deficiency found were 24.3% (n=80) and 17% (n=56) among the study population, respectively. Patients were assigned to receive either oral vitD (50.000 IU) (treatment group; n=40 insufficiency patients, n=28 deficiency patients) or not 48 hours before CABG surgery. Patients were followed up during hospitalisation process with respect to new-onset AF. All investigators were blinded to treatment assignment. VitD supplementation was initiated in control group while discharging. The patients\' data were analysed for AF in the postoperative period until discharge. The study was approved by the local ethics committee.

Definition of POAF
------------------

The study\'s main outcome was the occurrence of POAF from surgery until hospital discharge. Continuous electrocardiogram (ECG) monitoring was performed up to 48 hours after the operation to detect new-onset AF. Subsequently, telemetric ECG device was placed on the patients until the fifth postoperative day. The presence of ECG-documented AF for at least 5 min was recorded and analysed as POAF without symptoms. All symptomatic episodes detected by the patients or clinical residents were confirmed by a 12-lead ECG, and at least 1 min was recorded and analysed as POAF. Patients who developed AF in the postoperative period until discharge were included in the POAF group.

Patients who developed POAF were treated with intravenous beta-blocker as a first-line rate control therapy. Intravenous amiodarone was initiated as a first-line rhythm control therapy. If the heart rate was not tolerated despite medical therapy (amiodarone, beta-blocker), electrical cardioversion was performed if POAF had been occurred for \<48 hours. If POAF had been occurred for ≥48 hours, left atrial clot was ruled out with transesophageal echocardiography before electrical cardioversion. Anticoagulation therapy was initiated in patients with POAF and continued for at least three months. The decision to continue oral anticoagulation after three months was made according to the CHA2DS2-VASC score \[congestive HF, HT, age ≥75 years (2 points), diabetes mellitus (DM), previous stroke/transient ischemic attack (TIA) (2 points), vascular disease, age 65-74 years, and gender (female)\].

Patient\'s data including age, gender, history of HT, hyperlipidemia (HL), chronic kidney disease, DM, HF, chronic obstructive pulmonary disease (COPD), congenital heart disease, valvular heart disease, liver disease, stroke, thyroid disease, preoperative drug use \[beta-blockers, diuretics, aspirin, angiotensin-converting enzyme inhibitor/angiotensin receptor blockers (ACE-i/ARB), and statins\], echocardiographic variables such as ejection fraction (EF) and left atrial diameter, and presence of valvular disease were retrieved from the medical charts and included in the analysis.

Echocardiographic Examination
-----------------------------

All patients underwent transthoracic echocardiography using Vivid S5 (GE healthcare) echocardiography device and Mass S5 probe (2-4 MHz). Standard two-dimensional and colour flow Doppler evaluation were acquired according to the American Society of Echocardiography and European Society of Echocardiography guidelines^\[[@r8]\]^. EF was measured according to the Simpson\'s method. Left atrial diameter was measured in parasternal long axis view using two-dimensional echocardiography at the left ventricular end-systole.

The study\'s exclusion criteria were: patients with paroxysmal or persistent AF, being on antiarrhythmic medications, patients who underwent pharmacological or electrical cardioversion before CABG surgery due to reasons other than AF, and patients who underwent other cardiac procedures in addition to CABG or who planned to undergo emergency surgery. Furthermore, patients without vitD insufficiency or deficiency were also excluded from the study.

Laboratory Tests
----------------

25-hydroxy (OH) vitD, calcium, and other biochemical and hematologic parameter levels were measured following a fasting period of 8 hours. Serum 25-(OH) vitD levels were measured by chemiluminescent immunoassay using a LIAISON analyser (DiaSorin Inc). VitD deficiency was defined as serum levels of 25-(OH) vitD \<20 ng/ml. VitD insufficiency was defined as a level of 20-29 ng/ml. Plasma levels of 25-(OH) vitD \>30 ng/ml were defined as normal. Oral vitD supplementation (50.000 U) was initiated 48 hours before CABG surgery.

Statistical Analysis
--------------------

Statistical analysis was performed using the SPSS (version 20.0, SPSS Inc., Chicago, IL, USA) software package. Continuous variables were expressed as mean ± standard deviation (mean± SD) and categorical variables were expressed as a percentage (%). The Kolmogorov-Smirnov test was used to evaluate variables distribution. Student\'s t-test was used to evaluate continuous variables showing normal distribution and Mann-Whitney U-test was used to evaluate variables that did not show normal distribution. A *P*-value \<0.05 was considered statistically significant.

RESULTS
=======

The present study included 328 consecutive patients, of which 80 (24.3%) patients had vitD insufficiency and 56 (17%) had vitD deficiency. [Table 1](#t1){ref-type="table"} presents the main characteristics of the patients with and without vitD supplementation. There was no significant difference between these two groups with regards to age (63.8±9.3 years *vs.* 62.7±8.9 years, *P*=0.761), female gender (46.3% *vs.* 48.1%, *P*=0.827), HT (62.5% *vs.* 63.7%, *P*=0.834), DM (37.9% *vs.* 35.4%, *P*=0.637), HL (32.8% *vs.* 34.7%, *P*=0.682), smoking history (24.6% *vs.* 27.1%, *P*=0.753), COPD (28.7% *vs.* 26.9%, *P*=0.756), left atrial diameter (38.9 mm *vs.* 39.3 mm, *P*=0.837), left ventricular EF (62.7±6.9% *vs.* 61.3±7.1%, *P*=0.843), and duration of hospitalization (8.1±2.3 days *vs.* 7.9±2.1 days, *P*=0.891) ([Table 1](#t1){ref-type="table"}).

###### 

Patient\'s characteristics.

  Patient\'s characteristics               Vitamin D supplementation   *P*              
  ---------------------------------------- --------------------------- ---------------- -------
  Age (years)                              63.8±9.3                    62.7±8.9         0.761
  Female gender (%)                        46.3                        48.1             0.827
  Hypertension (%)                         62.5                        63.7             0.834
  Diabetes mellitus (%)                    37.9                        35.4             0.637
  Hyperlipidemia (%)                       32.8                        34.7             0.682
  Smoking history (%)                      24.6                        27.1             0.753
  COPD, n (%)                              28.7                        26.9             0.756
  Duration of hospitalization (days)       8.1±2.3                     7.9±2.1          0.891
  Left ventricular ejection fraction (%)   62.7±6.9                    61.3±7.1         0.843
  Left atrial diameter (mm)                38.9                        39.3             0.837
  Cross-clamp time (min)                   74 (71.0-78.0)              75 (72-80)       0.672
  Cardiopulmonary bypass time (min)        96 (84.0-101)               94 (80.0-98.0)   0.718
  Beta-blocker therapy (%)                 86                          89               0.584
  Statin therapy (%)                       92                          94               0.783
  ACE-ı/ARB therapy (%)                    72                          70               0.867
  Aspirin therapy (%)                      96                          93               0.567
  Diuretics therapy (%)                    23                          21               0.738

ACE-ı/ARB=angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; COPD=chronic obstructive pulmonary disease

Also, there was no significant difference between these two groups with regards to medications, such as beta-blockers (86% *vs.* 89%, *P*=0.584), statin (92% *vs.* 94%, *P*=0.783), ACE-ı/ARB (72% *vs.* 70%, *P*=0.867), aspirin (96% *vs.* 93%, *P*=0.567), and diuretics (23% *vs.*. 21%, *P*=0.738) ([Table 1](#t1){ref-type="table"}). And there was no significant difference between them with regards to cross-clamp time (74 min *vs.* 75 min, *P*=0.672) and cardiopulmonary bypass time (96 min *vs.* 94 min, *P*=0718) ([Table 1](#t1){ref-type="table"}).

In addition, there was no significant difference between these two groups with regards to biochemical and haematological parameters, such as hemoglobin (14.1±2.3 *vs.* 14.6±2.8 g/dl, *P*=0.652), platelet (293.5±46.9 *vs.* 289.3±49.6 10^3^/µL, *P*=0.563), white blood cell (7.9±3.7 *vs.* 8.2±3.4 10^3^/µL, *P*=0.857), creatinine (1.03±0.29 *vs.* 1.01±0.23 mg/dl, *P*=0.761), fasting plasma glucose (112.3±32.9 *vs.* 109.2±30.7 mg/dl, P=0.627), C-reactive protein (1.14±0.92 *vs.* 1.22±0.91 mg/dl, *P*=0.738), total cholesterol (186.3±43.1 *vs.* 181.3±44.9 mg/dl, *P*=0.613), high-density lipoprotein (37.1±9.7 *vs.* 39.3±11.5 mg/dl, *P*=0.514), low-density lipoprotein (163.4±43.8 vs 165.9±45.7 mg/dl, *P*=0.628), and triglyceride (183.1±56.7 *vs.* 178.1±54.7 mg/dl *P*=0.485) ([Table 2](#t2){ref-type="table"}).

###### 

Laboratory parameters.

  Laboratory parameters                           Vitamin D supplementation   *P*                  
  ----------------------------------------------- --------------------------- -------------------- -------
  Hemoglobin (g/dl)                               14.1±2.3 (14.7)             14.6±2.8 (14.9)      0.652
  Platelet (10^3^/µL)                             293.5±46.9 (302.8)          289.3±49.6 298.3)    0.563
  White blood cell (10^3^/µL)                     7.9±3.7 (8.7)               8.2±3.4 (8.9)        0.857
  Creatinine (mg/dl)                              1.03±0.29 (1.12)            1.01±0.23 (1.08)     0.761
  Fasting plasma glucose (mg/dl)                  112.3±32.9 (104.6)          109.2±30.7 (106.9)   0.627
  C-reactive protein (mg/dl)                      1.14±0.92 (0.97)            1.22±0.91 (0.99)     0.738
  Total cholesterol (mg/dl)                       186.3±43.1 (195.1)          181.3±44.9 (192.7)   0.613
  High-density lipoprotein (mg/dl)                37.1±9.7 (39.3)             39.3±11.5 (41.4)     0.514
  Low-density lipoprotein (mg/dl)                 163.4±43.8 (184.2)          165.9±45.7 (182.7)   0.628
  Triglyceride (mg/dl)                            183.1±56.7 (192.6)          178.1±54.7 (189.4)   0.485
  Vitamin D level (deficiency group) (ng/ml)      11.4±4.9                    10.9±5.2             0.681
  Vitamin D level (ınsufficiency group) (ng/ml)   24.6±3.7                    24.9±3.9             0.837

Regarding to mean vitD level of insufficiency (24.6±3.7 *vs.* 24.9±3.9 ng/ml, *P*=0.837) and deficiency patients (11.4±4.9 *vs.* 10.9±5.2 ng/ml, *P*=0.681), there was no significant difference between treatment and control groups ([Table 2](#t2){ref-type="table"}).

Although the occurrence of POAF was not significantly different among treatment and control groups in patients with vitD insufficiency (31% *vs.* 33%, *P*=0.538), there was a significant difference between these two groups with regards to POAF in patients with vitD deficiency (18% *vs.* 29%, *P*=0.02) ([Table 3](#t3){ref-type="table"}).

###### 

Prevalence of postoperative atrial fibrillation (POAF).

                                       Vitamin D supplementation               *P*          
  ------------------------------------ --------------------------------------- ----- ------ -------
  POAF (%)                             Vitamin D insufficiency group, n (80)   31    33     0.538
  Vitamin D deficiency group, n (56)   18                                      29    0.02   

DISCUSSION
==========

This study demonstrated that preoperative vitD supplementation was significantly preventive to the occurrence of POAF in patients with vitD deficiency while it was not preventive to the occurrence of POAF in those with vitD insufficiency. Beneficial effects of preoperative vitD supplementation might be associated with tend to more occurrence of POAF in patients with vitD deficiency.

AF is the most common sustained arrhythmia and it has a major impact on the morbidity and mortality of general population. The risk of AF increases up to 26% after the age of 40. It is estimated that AF may account for 10% to 15% of all strokes, with an associated mortality of up to 1.9-fold^\[[@r9]\]^. In previous studies, ageing, male gender, COPD, HF, DM, preoperative AF attacks, chronic renal disease, metabolic syndrome, increased cross-clamp times, increased inflammatory markers, and left atrial diameter were found to be independent variables predicting the development of POAF^\[[@r10]\]^.

Several potential mechanisms have described the association between vitD and AF^\[[@r11]\]^. VitD insufficiency was associated with endothelial dysfunction and subclinical atherosclerosis^\[[@r12]\]^. VitD regulates inflammatory responses and up-regulates the expression of anti-inflammatory cytokines, such as interleukin 10 (IL-10) and IL-6, according to in-vitro experiments^\[[@r13]\]^. Also, vitD regulates RAAS activity. Activated RAAS can lead to an increase in new-onset AF^\[[@r14]\]^. It is postulated that tissue RAAS can induce apoptosis of cardiomyocytes and can contribute to changes in atrial structure^\[[@r15]\]^.

There were inconsistent results regarding low vitD levels and AF. Demir et al.^\[[@r16]\]^ reported a strong relationship between vitD deficiency and non-valvular AF. Serum vitD level was significantly associated with AF in Chinese patients with persistent nonvalvular AF^\[[@r17]\]^. Hanafy et al.^\[[@r18]\]^ revealed the direct electromechanical effects on the left atrium after vitD administration and found that it could effectively prevent and terminate AF.

On the other hand, Rienstra et al.^\[[@r19]\]^ reported that vitD deficiency does not promote the development of AF. Additionally, Qayyum et al.^\[[@r20]\]^ also showed that there was no significant association between vitD deficiency and AF. Another prospective cohort study did not support the hypothesis that vitD level is associated with AF^\[[@r21]\]^.

In the same manner, there were inconsistent results regarding preoperative serum vitD level and POAF. POAF incidence was significantly higher in patients with vitD deficiency or insufficiency than in patients with normal vitD level in previous studies^\[[@r2],[@r3]\]^. In our previous study, although there was a significant negative correlation between vitD and left atrial diameter, vitD level was not an independent predictor for POAF^\[[@r7]\]^.

Several studies demonstrated that platelets play a critical and precipitating role in AF occurrence as the volume and distribution width of platelets and the factors of platelet activity appeared to be significantly higher in AF patients than in sinus rhythm patients. Haematological indices red blood cell distribution width (RDW) and mean platelet volume (MPV) are currently recognised as risk factors for POAF. MPV, as a valuable haematological parameter in complete blood count test, could strongly predict the occurrence of paroxysmal, persistent, or permanent AF^\[[@r22]-[@r25]\]^. Our study did not include aforementioned haematological parameters such as MPV and RDW. In our study, there was no significant association between platelet count and POAF.

There are scarce data regarding the preventive role of preoperative vitD supplementation on POAF in patients with vitD insufficiency and deficiency. Therefore, we aimed to evaluate the preventive role of vitD supplementation. This study revealed that preoperative vitD supplementation was significantly preventive to the occurrence of POAF in patients with vitD deficiency while it was not preventive to the occurrence of POAF in those with vitD insufficiency. Preventive effect of vitD supplementation might be associated with direct electromechanical effects on the left atrium, regulating RAAS and inflammatory responses. Further randomised clinical studies with larger study population are needed in this field.

Limitations of the Study
------------------------

Our study has some limitations: first, AF was diagnosed by ECG monitoring only during hospitalisation process; second, this study has a small sample size; third, vitD level was measured at a single point in time; fourth, the lack of parathyroid hormone levels measurement; and fifth, the lack of haematological markers such as MPV and RDW.

CONCLUSION
==========

To the best of our knowledge, this study is the first to evaluate the preventive effect of vitD on POAF in patients with vitD insufficiency and deficiency. In this study, preoperative vitD supplementation was found to be significantly preventive to the occurrence of POAF in patients with vitD deficiency while it was not found to be preventive to the occurrence of POAF in those with vitD insufficiency. VitD deficiency should be considered in patients with POAF especially resistant to medical and electrical cardioversion. Further prospective and randomised studies with larger number of patients are required due to the relatively small number of patients in the present study.
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